News

1 2 3 4 5 6 8 11 14
NEWS

SOTIO starts Phase I/II trial of DCVAC in combination with ONCOS-102: the Targovax adenovirus based immunotherapy

SOTIO, a biotechnology company owned by the PPF Group, announces today that the first patient was enrolled to the SP015 clinical trial of a combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming engineered human serotype 5 adenovirus, for patients with prostate cancer. The trial is planned for the United Kingdom and the Czech Republic. SOTIO is collaborating with Targovax,a clinical stage immuno-oncology company developing ONCOS-102.

NEWS

SOTIO to Present Results from Phase II Clinical Trial of 1st-Line Ovarian Cancer Treatment in Oral Presentation at ASCO 2018 Annual Meeting

SOTIO, a biotechnology company owned by the PPF Group, today announces the presentation of new promising clinical data from its ovarian and lung cancer clinical trials evaluating DCVAC, an active cellular immunotherapy product. Data will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1-5 June, in Chicago, IL, United States.

NEWS

SOTIO Receives Positive Opinion for Orphan Drug Designation for DCVAC/OvCa from European Medicines Agency (EMA)

SOTIO, a biotechnology company owned by the PPF Group, today announces that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for DCVAC/OvCa for the treatment of patients with ovarian cancer. The EMA’s positive opinion follows a similar decision issued previously by the U.S. Food and Drug Administration (FDA).

This website uses cookies; by continuing to use this page, you consent to their use. About cookies